

Message

From: Hogan, Karen [Hogan.Karen@epa.gov]
Sent: 1/30/2017 9:06:56 PM
To: Newhouse, Kathleen [Newhouse.Kathleen@epa.gov]
Subject: RE: benzo[a]pyrene

That elephant is getting bigger...

From: Newhouse, Kathleen
Sent: Monday, January 30, 2017 4:02 PM
To: D'Amico, Louis <DAmico.Louis@epa.gov>
Cc: Pratt, Margaret <pratt.margaret@epa.gov>; Hogan, Karen <Hogan.Karen@epa.gov>
Subject: FW: benzo[a]pyrene

FYI.

More similar questions. The answer to the first is simple.

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

For the second question

Ex. 5 Deliberative Process (DP)

Lou, let me know if you have other suggestions for how to communicate this. I anticipate we will continue to get asked these questions.

-K

From: Ross Wilson
Sent: Monday, January 30, 2017 12:41 PM
To: Newhouse, Kathleen <Newhouse.Kathleen@epa.gov>
Subject: benzo[a]pyrene

Kathleen

Congratulations on US EPA's new document on benzo[a]pyrene. It looks very impressive! Two questions:

- For evaluation of non-cancer risks, does US EPA have any suggestion on how to evaluate non-cancer risks to the other PAHs? For example, would US EPA recommend using the RfD or RFC for benzo[a]pyrene to evaluate the non-cancer risk to chrysene?
- For evaluation of cancer risks, does US EPA have recommended potency equivalency factors for the other PAHs.

Thanks for any information you may be able to share.

Ross Wilson, M.Sc., DABT
Wilson Scientific Consulting Inc.

Ex. 6 Personal Privacy (PP)

Telephone: Ex. 6 Personal Privacy (PP)

Cell phone: Ex. 5 Deliberative Process (DP)

Email: Ex. 6 Personal Privacy (PP)

